Aarti Pharmalabs

Mumbai, India Founded: 2019 • Age: 7 yrs Listed
Active pharmaceutical ingredients and intermediates are manufactured by Aarti Pharmalabs.
Request Access
Report Incorrect Data
Page last updated

About Aarti Pharmalabs

Aarti Pharmalabs is a publicly listed company based in Mumbai (India) founded in 2019. Active pharmaceutical ingredients and intermediates are manufactured by Aarti Pharmalabs. The company has 2,004 employees. Its chief executive, as recorded, is Narendra Jagannath Salvi. Its Indian entity Aarti Pharmalabs Limited reported revenue of ₹1,837 Cr. Aarti Pharmalabs offers products and services including Active Pharmaceutical Ingredients and CDMO Services. Its focus areas include Traditional Pharmaceuticals and Active Pharmaceutical Ingredients.

Company details

Aarti Pharmalabs Limited was established in 2019 in Mumbai, India. Operations focus on the pharmaceuticals and nutraceuticals sector, with development and production of active pharmaceutical ingredients (APIs), new chemical entities (NCEs), and API intermediates. Manufacturing services for APIs and drug substances are extended to international clients, supporting their supply requirements in these areas.

  • Headquarters Mumbai, India
  • Employees 2,004
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website aartipharmalabs.com
  • Social LinkedIn Facebook
  • Legal Name Aarti Pharmalabs Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹8,060 Cr

    AARTIPHARM · NSE

  • Share Price
    ₹919.95

    +3.50% today

  • Revenue
    ₹1,819 Cr

    FY 2025-26 · -14.0% YoY

  • EBITDA
    ₹366 Cr

    Margin 20.1%

  • Net Profit
    ₹177 Cr

    FY 2025-26 · -35.1% YoY

  • P/E (TTM)
    30.4x

    P/B 3.5x

  • ROE
    8.5%

    ROCE 10.5%

  • Debt / Equity
    0.28

    Interest cover 17.9x

  • Employee Count
    2,004

Products & Services of Aarti Pharmalabs

Aarti Pharmalabs offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients and CDMO Services.

Active Pharmaceutical Ingredients
Pharmaceutical Products

Active Pharmaceutical Ingredients are manufactured for use in clinical testing and commercial production

CDMO Services
Development Services

CDMO services are provided, including process R&D and validations for drug substances

Board of directors of Aarti Pharmalabs Limited (Aarti Pharmalabs)

Aarti Pharmalabs Limited is the primary company behind Aarti Pharmalabs. The board of Aarti Pharmalabs Limited currently have 12 directors; the longest-serving is Hetal Gogri Gala, appointed in 2021. 4 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Hetal Gogri Gala
DIN 00005499
Managing Director07 Aug 20215 yrs 2 moAarti Pharmalabs Limited
Rajendra Vallabhaji Gogri
DIN 00061003
Director07 Aug 20215 yrs 2 moAarti Pharmalabs Limited
Rashesh Chandrakant Gogri
DIN 00066291
Director07 Aug 20215 yrs 2 moAarti Pharmalabs Limited
Narendra Jagannath Salvi
DIN 00299202
Managing Director07 Aug 20215 yrs 2 moAarti Pharmalabs Limited
Vilas Gaikar Gajanan
DIN 00033383
Director17 Oct 20224 yrsAarti Pharmalabs Limited
Rupal Anand Vora
DIN 07096253
Director17 Oct 20224 yrsAarti Pharmalabs Limited
Parimal Hasmukhlal Desai
DIN 00009272
Director17 Oct 20224 yrsAarti Pharmalabs Limited
Bhavesh Rasiklal Vora
DIN 00267604
Director17 Oct 20224 yrsAarti Pharmalabs Limited
Vinay Gopal Nayak
DIN 02577389
Director17 Oct 20224 yrsAarti Pharmalabs Limited
Jeenal Kenil Savla
DIN 07545244
Director17 Oct 20224 yrsAarti Pharmalabs Limited
Pradeep Hari Thakur
DIN 00685992
Director13 May 20242 yrs 5 moAarti Pharmalabs Limited
Nehal Garewal
DIN 01750146
Director13 May 20242 yrs 5 moAarti Pharmalabs Limited

People of Aarti Pharmalabs

33 people are tracked at Aarti Pharmalabs (13 in leadership, 20 in team); the tracked headcount is 2,004.

NameRoleGroup
Narendra Jagannath Salvi
CEO & MDLeadership
Manoj Singh Bhadoriya
General Manager OperationsLeadership
Sudam Vanarse
Sr. Manager HR & Admin (cluster HR Head)Leadership
Sachin Patil
General ManagerLeadership
Hetal Gogri Gala
Vice Chairperson & Managing DirectorLeadership
Shri Narendra Salvi
Managing DirectorLeadership
Jasmin Mehta
General ManagerLeadership
Manohar Khairnar
EHS HeadLeadership
Lalit Kumar
Dy. General Manager (r&d) - Flow ChemistryLeadership
Dr. Hemant Gundare
Head Corporate EHS & Sustainability - Aarti GroupLeadership
Harshul Patel
Deputy General ManagerLeadership
Mutyala Naidu G
Head OperationsLeadership
Charles-Svend P.
Head Of Business Development - EuropeLeadership
Pranav Bhatt
Sr ManagerTeam
Mistry Mitesh
ExecutiveTeam
Jayesh Patil
Jr. Executive - Process SafetyTeam
Gokul Chavanke
Senior ExecutiveTeam
Vishal Salunke
Deputy ManagerTeam
Mukesh Kumar
Production ExecutiveTeam
Vaibhav Mehta
Sr. Manager ProcurementTeam

13 more people are available in the full profile.

Premium access

Complete people profiles for Aarti Pharmalabs

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Aarti Pharmalabs

Aarti Pharmalabs is a publicly listed company on the NSE with ticker symbol AARTIPHARM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date03 Feb 2023
  • Listed onNSE: AARTIPHARM
  • Listed entityAarti Pharmalabs Limited
  • Exchange sectorHealth technology
  • ISININE0LRU01027
  • Share price₹867.65 (-1.91% on the day) · 2026-10-14
  • Market capitalisation₹8,020 Cr
  • Price to earnings36.9
  • EPS (diluted, trailing year)₹23.50
  • Dividend yield0.4%
  • Volume (last session)607,704

Financials of Aarti Pharmalabs

Exchange-reported figures of Aarti Pharmalabs Limited, the listed company behind Aarti Pharmalabs (NSE: AARTIPHARM).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,819 Cr
-14.0% YoY
EBITDA
₹366 Cr
-21.4% YoY
Profit After Tax
₹177 Cr
-35.1% YoY
Net Worth
₹2,125 Cr
+6.8% YoY
Total Assets
₹2,926 Cr
+21.0% YoY
Total Debt
₹754 Cr
+82.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,8192,1151,8531,9451,2000.00
Revenue growth-14.0%+14.2%-4.8%+62.1%--
EBITDA3664663863422070.00
EBITDA margin+20.1%+22.0%+20.8%+17.6%+17.3%-
Profit before tax2333613002611550.00
Net profit1772722161931220.00
Net profit margin+9.7%+12.9%+11.7%+9.9%+10.2%-
EPS (₹)19.2730.0623.9321.354,890.10(0.18)
Balance sheet
Total assets2,9262,4192,0481,7791,7260.25
Net worth2,1251,9901,7571,5581,3860.23
Total debt7544132852153380.02
Cash & bank9.628.6524.0712.1983.270.25
Net working capital9769158497267850.25
Cash flow
Cash from operations262330216250(43.70)0.00
Cash from investing(431)(412)(215)(158)(139)0.00
Cash from financing17165.439.72(163)2600.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue610536583432418386564538
Revenue growth (YoY)+45.9%+38.7%+3.4%-19.6%-8.7%-30.5%--
Other income7.357.8613.564.550.051.60(1.61)5.03
EBITDA13313611399.5174.0793.45146129
EBITDA margin+21.8%+25.4%+19.4%+23.0%+17.7%+24.2%+25.8%+23.9%
Depreciation30.5330.0328.1628.6224.7722.7922.8223.04
Interest14.9512.8816.8612.5810.676.796.589.97
Profit before tax94.9910181.6762.8638.6865.47115101
Tax23.5224.9220.5614.9210.7715.9526.2726.64
Net profit71.4776.1461.1147.9427.9149.5288.3573.99
EPS (₹)7.878.396.745.293.085.469.748.16
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,7981,7711,5021,5119410.000.00
Revenue growth+1.5%+17.9%-0.6%+60.6%---
EBITDA3704283463081800.00(0.02)
EBITDA margin+20.6%+24.2%+23.0%+20.4%+19.1%--
Profit before tax2343362752331340.00(0.02)
Net profit1782572011721070.00(0.02)
Net profit margin+9.9%+14.5%+13.4%+11.4%+11.3%--
EPS (₹)19.4428.3922.1418.954,269.05(0.18)(0.75)
Balance sheet
Total assets2,7842,2771,8991,6511,6120.250.25
Net worth1,9821,8441,6211,4391,2840.230.23
Total debt7544112722083270.000.00
Cash & bank6.623.524.430.3756.500.250.25
Net working capital9848708166977340.250.25
Cash flow
Cash from operations257339184216(64.84)0.00(0.02)
Cash from investing(425)(418)(184)(116)(134)0.000.00
Cash from financing17178.634.40(157)2550.000.27
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue613535580425417375530471
Revenue growth (YoY)+46.8%+42.4%+9.5%-9.7%+10.6%-4.6%--
Other income0.472.9310.53(0.37)3.151.60(2.51)11.94
Total expenses478398463325343280386356
EBITDA13413611710073.9895.13143115
EBITDA margin+21.9%+25.5%+20.2%+23.6%+17.7%+25.3%+27.0%+24.4%
Depreciation30.5330.0328.1628.6224.7722.7620.8321.04
Interest14.9512.8716.8612.5810.666.796.299.70
Profit before tax89.2896.2382.5858.5841.7067.1811396.19
Tax23.5224.9220.5614.7410.7715.9524.6622.66

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 03 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue610536583432418386564538
Revenue growth (YoY)+45.9%+38.7%+3.4%-19.6%-8.7%-30.5%--
Other income7.357.8613.564.550.051.60(1.61)5.03
EBITDA13313611399.5174.0793.45146129
EBITDA margin+21.8%+25.4%+19.4%+23.0%+17.7%+24.2%+25.8%+23.9%
Depreciation30.5330.0328.1628.6224.7722.7922.8223.04
Interest14.9512.8816.8612.5810.676.796.589.97
Profit before tax94.9910181.6762.8638.6865.47115101
Tax23.5224.9220.5614.9210.7715.9526.2726.64
Net profit71.4776.1461.1147.9427.9149.5288.3573.99
EPS (₹)7.878.396.745.293.085.469.748.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,8192,1151,8531,9451,2000.00
Revenue growth-14.0%+14.2%-4.8%+62.1%--
Other income17.748.434.902.322.510.00
Total expenses1,4531,6491,4671,6039930.00
Employee cost16314912812179.500.00
EBITDA3664663863422070.00
EBITDA margin+20.1%+22.0%+20.8%+17.6%+17.3%-
Depreciation10486.9073.2462.5442.120.00
Interest46.9026.9017.2121.0511.960.00
Profit before tax2333613002611550.00
Tax58.2288.2983.5967.2833.130.00
Net profit1772722161931220.00
Net profit margin+9.7%+12.9%+11.7%+9.9%+10.2%-
EPS (₹)19.2730.0623.9321.354,890.10(0.18)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital45.3345.3245.3145.310.250.25
Reserves & surplus2,0791,9451,7121,5131,341(0.02)
Shareholders' funds (net worth)2,1251,9901,7571,5581,3860.23
Minority interest0.000.000.000.000.000.00
Secured loans6863962640.003380.02
Unsecured loans68.7316.7621.152150.000.00
Total debt7544132852153380.02
Total liabilities2,9262,4192,0481,7791,7260.25
Assets
Gross block2,1351,7961,6091,4311,2250.00
Net block1,4371,1371,0339267820.00
Capital work in progress3933741371021870.00
Investments19476.8010786.5232.230.00
Inventories6405886436024750.00
Sundry debtors5835755194503770.00
Cash & bank balances9.628.6524.0712.1983.270.25
Loans & advances16499.0088.9847.6892.760.00
Total current assets1,3971,2711,2751,1121,0280.25
Total current liabilities4213554263862430.00
Net working capital9769158497267850.25
Total assets2,9262,4192,0481,7791,7260.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash6.7323.6312.1283.275.330.25
Net cash from operating activities262330216250(43.70)0.00
Net cash from investing activities(431)(412)(215)(158)(139)0.00
Net cash from financing activities17165.439.72(163)2600.00
Net change in cash1.80(16.90)11.51(71.15)77.940.00
Closing cash9.628.6524.0712.1983.270.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-14.0%+14.2%-4.8%+62.1%--
EBITDA growth-21.4%+20.7%+12.9%+65.3%--
PBT growth-35.4%+20.0%+15.2%+67.8%+9997.0%+9997.0%
Net income growth-35.1%+25.8%+11.9%+58.3%--
Revenue CAGR (3Y)-2.2%+20.8%----
EBITDA CAGR (3Y)+2.3%+31.1%----
Profitability & leverage
Net income margin+9.6%+12.9%+11.7%+10.0%+10.2%-
Return on capital employed+10.5%+17.4%+16.6%+16.1%+19.4%0.0%
Return on net worth+8.5%+14.5%+13.1%+13.1%+17.6%0.0%
Debt / equity0.280.190.150.190.240.09
Long-term debt / equity0.090.040.010.000.000.01
Interest cover17.907.095.507.537.26-
Efficiency & per share
Fixed asset turnover0.931.241.221.461.960.00
Inventory turnover2.963.442.983.615.050.00
Debtors turnover3.143.863.824.716.370.00
EPS (₹)19.2730.0623.9321.354,890.10(0.18)
Dividend per share (₹)3.505.003.002.000.000.00
Book value per share (₹)234.35219.55193.88171.9753,646.669.12
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue613535580425417375530471
Revenue growth (YoY)+46.8%+42.4%+9.5%-9.7%+10.6%-4.6%--
Other income0.472.9310.53(0.37)3.151.60(2.51)11.94
Total expenses478398463325343280386356
EBITDA13413611710073.9895.13143115
EBITDA margin+21.9%+25.5%+20.2%+23.6%+17.7%+25.3%+27.0%+24.4%
Depreciation30.5330.0328.1628.6224.7722.7620.8321.04
Interest14.9512.8716.8612.5810.666.796.299.70
Profit before tax89.2896.2382.5858.5841.7067.1811396.19
Tax23.5224.9220.5614.7410.7715.9524.6622.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,7981,7711,5021,5119410.000.00
Revenue growth+1.5%+17.9%-0.6%+60.6%---
Other income15.3212.8011.011.282.510.000.00
Total expenses1,4271,3431,1561,2037610.000.02
Employee cost16014012011479.980.000.00
EBITDA3704283463081800.00(0.02)
EBITDA margin+20.6%+24.2%+23.0%+20.4%+19.1%--
Depreciation10479.0666.0155.7737.230.000.00
Interest46.9025.6316.6320.4911.340.000.00
Profit before tax2343362752331340.00(0.02)
Tax58.0478.9973.8861.6327.000.000.00
Net profit1782572011721070.00(0.02)
Net profit margin+9.9%+14.5%+13.4%+11.4%+11.3%--
EPS (₹)19.4428.3922.1418.954,269.05(0.18)(0.75)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital45.3345.3245.3145.310.250.250.25
Reserves & surplus1,9371,7991,5761,3931,239(0.02)(0.02)
Shareholders' funds (net worth)1,9821,8441,6211,4391,2840.230.23
Secured loans6863952512070.000.000.00
Unsecured loans68.7316.6321.150.983270.000.00
Total debt7544112722083270.000.00
Total liabilities2,7842,2771,8991,6511,6120.250.25
Assets
Gross block2,1291,6531,4721,3041,1010.000.00
Net block1,4371,0599538487010.000.00
Capital work in progress3933691371021870.000.00
Investments44.0257.0361.6655.4839.870.000.00
Inventories6365445825384440.000.00
Sundry debtors5875534493723040.000.00
Cash & bank balances6.623.524.430.3756.500.250.25
Loans & advances16492.6180.8343.7085.180.000.00
Total current assets1,3931,1931,1169538900.250.25
Total current liabilities4103223002571560.000.00
Net working capital9848708166977340.250.25
Total assets2,7842,2771,8991,6511,6120.250.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.844.000.3056.500.250.250.00
Net cash from operating activities257339184216(64.84)0.00(0.02)
Net cash from investing activities(425)(418)(184)(116)(134)0.000.00
Net cash from financing activities17178.634.40(157)2550.000.27
Net change in cash2.70(1.16)3.70(56.20)56.250.000.25
Closing cash6.623.524.430.3756.500.250.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.5%+17.9%-0.6%+60.6%---
EBITDA growth-13.6%+23.7%+12.3%+71.5%-+100.0%-
PBT growth-30.4%+22.5%+17.6%+74.5%+9997.0%+9997.0%+9997.0%
Net income growth-30.7%+28.3%+16.8%+61.0%-+100.0%-
Revenue CAGR (3Y)+6.0%+23.5%-----
EBITDA CAGR (3Y)+6.3%+33.6%-----
Profitability & leverage
Net income margin+9.8%+14.5%+13.4%+11.4%+11.3%--
Return on capital employed+11.1%+17.3%+16.4%+15.6%+18.0%0.0%0.0%
Return on net worth+9.2%+14.9%+13.1%+12.6%+16.6%0.0%0.0%
Debt / equity0.300.200.160.200.250.010.01
Long-term debt / equity0.090.040.010.000.000.010.01
Interest cover17.647.345.948.117.95-0.00
Efficiency & per share
Fixed asset turnover0.951.131.081.261.710.000.00
Inventory turnover3.053.152.683.084.240.000.00
Debtors turnover3.163.543.664.476.190.000.00
EPS (₹)19.4428.3922.1418.954,269.05(0.18)(0.75)
Dividend per share (₹)3.505.003.002.000.000.000.00
Book value per share (₹)218.66203.44178.92158.7449,558.529.079.25

Web traffic of Aarti Pharmalabs

The website of Aarti Pharmalabs (aartipharmalabs.com) receives about 5.5K visits a month.

  • Monthly visits
    5.5K

    ▼ 21.8% vs previous month

Similar websites

Websites whose visitors overlap most with Aarti Pharmalabs. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Ami organics
amiorganics.com
100%
View details
Orex Pharma
orexpharma.com
24%
1.7K#7,913,792View details

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Aarti Pharmalabs (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Aarti Pharmalabs

AARTIPHARM: Q2 CONS NET PROFIT 754M RUPEES VS 279M (YOY)
Exchange Update • 6 days ago
AARTIPHARM: Q2 REVENUE 6.1B RUPEES VS 4.18B (YOY)
Exchange Update • 6 days ago
AARTI PHARMALABS: RS 62.93CR NSE BLOCK TRADE; FOR ~765697 SHARES, AT RS 821.9
Exchange Update • 1 month ago
Aarti Pharmalabs shares rally over 33% in two days post Q1 results. What is driving the surge? - The Economic Times
Economic Times • 2 months ago
Lumax Auto Technologies Ltd leads gainers in 'A' group | Capital Market News - Business Standard
Business Standard • 2 months ago
Aarti Pharmalabs shares hit 20% upper circuit as Q1 net profit surges 65% YoY to Rs 76 crore - The Economic Times
Economic Times • 2 months ago
Upper Circuit Share: Kwality Pharma, Aarti Pharmalabs, Universal Cables hit 20% upper circuits | Markets News - Business Standard
Business Standard • 2 months ago
Aarti Pharmalabs June-Quarter Consol Net Profit 761.4 Million Rupees
Reuters • 2 months ago
Aarti Pharmalabs Declares Dividend Of 2 Rupees Per Share
Reuters • 5 months ago
Aarti Pharmalabs Q4 Results: Shares slide 6% as forex loss, one-offs impact earnings performance - CNBC TV18
CNBCTV18 • 5 months ago
Premium access

Complete news archive for Aarti Pharmalabs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aarti Pharmalabs

Aarti Pharmalabs was founded in 2019.

Aarti Pharmalabs is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Narendra Jagannath Salvi is the CEO of Aarti Pharmalabs, as recorded in our data.

Aarti Pharmalabs has 2,004 employees.

The primary company behind Aarti Pharmalabs, Aarti Pharmalabs Limited, reported revenue of ₹1,837 Cr for FY 2026, down 14% year on year.

Aarti Pharmalabs Limited was established in 2019 in Mumbai, India. Operations focus on the pharmaceuticals and nutraceuticals sector, with development and production of active pharmaceutical ingredients (APIs), new chemical entities (NCEs), and API intermediates. Manufacturing services for APIs and drug substances are extended to international clients, supporting their supply requirements in these areas.

Aarti Pharmalabs offers Active Pharmaceutical Ingredients and CDMO Services.

Yes, Aarti Pharmalabs is publicly traded on NSE under the ticker symbol AARTIPHARM.

Aarti Pharmalabs operates through Aarti Pharmalabs Limited.

The legal entities of Aarti Pharmalabs currently have 14 directors, including Vilas Gaikar Gajanan, Rupal Anand Vora, Parimal Hasmukhlal Desai and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available